A phase II, randomized, open-label study to evaluate the safety and effectiveness of two antiretroviral therapeutic strategies: a dual PI-based HAART regimen versus a multi-NRTI ART regimen, in ART-experienced children and youth who have experienced virologic failure.

Trial Profile

A phase II, randomized, open-label study to evaluate the safety and effectiveness of two antiretroviral therapeutic strategies: a dual PI-based HAART regimen versus a multi-NRTI ART regimen, in ART-experienced children and youth who have experienced virologic failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2012

At a glance

  • Drugs Abacavir (Primary) ; Emtricitabine (Primary) ; Lopinavir/ritonavir (Primary) ; Saquinavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Lamivudine; Zidovudine
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2012 Actual patient number 6 added as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Actual end date (May 2007) added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top